El "Diagnóstico de enfermedades" está en plena actualidad inversora

,
Integral service around a transaction
BY : Diego Gutiérrez10/04/2013

Este sector de actividad está inmerso en un activo movimiento tanto de operaciones corporativas de consolidación como la protagonizada por Progenika y Griffols como por varias "startups" que pretenden hacerse un hueco en el complicado mundo sanitario.

Operaciones corporativas: Grifols adquiere Progenika

La multinacional catalana de hemoderivados Grifols ha comprado el 60% del capital de la empresa biotecnológica vasca Progenika Biopharma por un total de 37 millones de euros en Marzo del 2013.
Grifols es la tercera compañía del mundo en la producción de fármacos biológicos derivados del plasma, y es un grupo pionero en investigación y desarrollo de alternativas terapéuticas.
Progenika, por su parte, está especializada en el desarrollo de tecnología para la medicina personalizada, y centra su actividad en el diseño y la producción de test genómicos y proteómicos para el diagnóstico in vitro, pronóstico de enfermedades, predicción de respuesta y monitorización de terapia farmacológica.
En 2012, Grifols multiplicó por cinco su beneficio, al pasar de ganar 50,3 millones en 2011 a 256,7 millones de euros con los que cerró el año pasado.
El crecimiento del beneficio en un 410,2 % de un año a otro se explica por la adquisición de su competidora estadounidense Talecris, cuya compra cerró en junio de 2011, y por la buena marcha de la compañía en el extranjero, especialmente en EEUU y Canadá.

Startups en acción: Sword Diagnostic y Chronix

Por otro lado, están saliendo nuevas iniciativas buscando nuevas rondas de financiación que hacen prever un todavía desarrollo de nuevos sistemas de diagnóstico. Algunos de estos casos son:
- Sword Diagnostics

La tecnología de detección de alto rendimiento Espada Diagnostics mejora considerablemente el rendimiento general de los ensayos y pruebas biomédicas.

Chronix 

Chronix Biomedical, Inc. es una compañía de diagnóstico molecular, que desarrolla sobre todo pruebas de sangre para el cáncer, incluyendo diagnósticos acompañantes y pruebas para la detección de enfermedad mínima residual.

Fondos más activos: presencia relevante de los VC ligados a las farmacéuticas
En los primeros meses del 2013 hemos visto como fondos de VC relacionados con multinacionales farmaceúticas han entrado en empresas del sector diagnóstico. Un ejemplo de ello han sido Roche Fund con su entrada en Marzo en Maculogix.

Diego Gutiérrez Zarza
ABRA INVEST
Web: www.abra-invest.com
Blog: http://abrainvest.wordpress.com/ 

The M&A Professionals

Meet our services

MEET
OUR
metodologY

Do you want to be up to date?

SUSCRIBE OUR NEWSLETTER

Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
"Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?

M&A NEWS
INDUSTRIAL REPORTS
closearrow-circle-o-downchevron-downcrossmenu